OSI Pharmaceuticals Announces the Appointment of Mr. Pierre Legault as Executive Vice President and Chief Financial Officer
December 16 2008 - 11:16AM
Business Wire
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today the
appointment of Mr. Pierre Legault as Executive Vice President,
Chief Financial Officer and Treasurer. Mr. Legault has over 16
years of senior management experience in the pharmaceutical
industry including several senior positions at Sanofi-Aventis and
Aventis, most notably Worldwide President of Sanofi-Aventis
Dermatology and Senior Vice President and Chief Financial Officer
of Aventis Pharmaceutical North America. Mr. Legault will add
extensive business and strategic expertise to the Company�s
leadership team and assume responsibility for all financial aspects
of the Company�s activities. Mr. Legault will report to the Chief
Executive Officer, Colin Goddard, Ph.D. and will be a leading
member of OSI�s Executive Management Team. He will assume the role
on December 29, 2008. �We are delighted that Pierre is joining the
OSI team,� stated Dr. Goddard. �Pierre has led finance and business
teams in companies throughout the healthcare industry ranging from
large pharma to major retail pharmacy chains and we are confident
that, with his extensive financial and management experience, he
will be a significant contributor to this Company�s future growth
and success.� Mr. Legault will succeed Mr. Michael G. Atieh who
will be stepping down from the CFO position on December 29, 2008,
pending his previously announced retirement which will now occur
effective January 5, 2009. �We�d like to take the opportunity to
thank Mike for his service to OSI, both over the last three years
as CFO and prior to that as a member of our Board of Directors, and
to wish him well in his future endeavours,� added Dr. Goddard. Mr.
Legault, 48, was most recently at Rite Aid Corporation where he was
Senior Executive Vice President and Chief Administrative Officer
following his instrumental role in the 2007 merger of Eckerd into
Rite Aid. Mr. Legault served as Executive Vice President of The
Jean Coutu Group, running its Brooks Eckerd operations in the
United States from January 2006 until June 2007. Prior to his time
at Sanofi-Aventis and Aventis, he was Global Senior Vice President
Finance and Treasury of Hoechst Marion Roussel and Chief Financial
Officer of Marion Merrell Dow (North America). Mr. Legault is a
Board member of numerous corporations, belongs to several
professional associations, including the Finance Executive
Institute and the Canadian Institute of Chartered Accountants.
About OSI Pharmaceuticals OSI Pharmaceuticals is committed to
"shaping medicine and changing lives" by discovering, developing
and commercializing high-quality and novel pharmaceutical products
designed to extend life and/or improve the quality of life for
patients with cancer and diabetes/obesity. The Company�s oncology
programs are focused on developing molecular targeted therapies
designed to change the paradigm of cancer care. OSI�s
diabetes/obesity efforts are committed to the generation of novel,
targeted therapies for the treatment of type 2 diabetes and
obesity. OSI's flagship product, Tarceva� (erlotinib), is the first
drug discovered and developed by OSI to obtain FDA approval and the
only EGFR inhibitor to have demonstrated the ability to improve
survival in both non-small cell lung cancer and pancreatic cancer
patients in certain settings. OSI markets Tarceva through
partnerships with Genentech, Inc. in the United States and with
Roche throughout the rest of the world. For additional information
about OSI, please visit . This news release contains
forward-looking statements. These statements are subject to known
and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements
made. Factors that might cause such a difference include, among
others, the completion of clinical trials, the FDA review process
and other governmental regulation, OSI's and its collaborators'
abilities to successfully develop and commercialize drug
candidates, competition from other pharmaceutical companies, the
ability to effectively market products, and other factors described
in OSI Pharmaceuticals' filings with the Securities and Exchange
Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024